Taken together, currently our results have identified several new pathological molecules secreted by aHSCs that are involved in diabetes-related MAFLD and even NASH, including Lamb2 and Tgfb1i1. These findings merit further research and exploration as potential targets for preventing severe liver fibrosis. Here, TGFB1I1 is linked to metabolic dysfunction-associated steatohepatitis.